Francis Eko to Bacterial Vaccines
This is a "connection" page, showing publications Francis Eko has written about Bacterial Vaccines.
Connection Strength
6.908
-
Richardson S, Medhavi FNU, Tanner T, Lundy S, Omosun Y, Igietseme JU, Eko FO. Role of route of delivery on Chlamydia abortus vaccine-induced immune responses and genital tract immunity in mice. Microbes Infect. 2025 Mar-Apr; 27(3):105463.
Score: 0.821
-
Tanner T, Medhavi FNU, Richardson S, Omosun YO, Eko FO. In silico design and analysis of a multiepitope vaccine against Chlamydia. Pathog Dis. 2024 02 07; 82.
Score: 0.776
-
Richardson S, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme JU, Carroll D, Eko FO. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine. Front Immunol. 2021; 12:698737.
Score: 0.647
-
Howard S, Richardson S, Benyeogor I, Omosun Y, Dye K, Medhavi F, Lundy S, Adebayo O, Igietseme JU, Eko FO. Differential miRNA Profiles Correlate With Disparate Immunity Outcomes Associated With Vaccine Immunization and Chlamydial Infection. Front Immunol. 2021; 12:625318.
Score: 0.632
-
Pais R, Omosun Y, Igietseme JU, Fujihashi K, Eko FO. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses. Front Immunol. 2019; 10:1577.
Score: 0.564
-
Pais R, Omosun Y, He Q, Blas-Machado U, Black C, Igietseme JU, Fujihashi K, Eko FO. Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice. PLoS One. 2017; 12(6):e0178537.
Score: 0.488
-
Pan Q, Pais R, Ohandjo A, He C, He Q, Omosun Y, Igietseme JU, Eko FO. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model. Vaccine. 2015 Apr 08; 33(15):1865-72.
Score: 0.416
-
Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011 May 12; 29(21):3802-10.
Score: 0.318
-
Eko FO, Ekong E, He Q, Black CM, Igietseme JU. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine. 2011 Feb 04; 29(7):1472-80.
Score: 0.312
-
Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum Vaccin. 2008 May-Jun; 4(3):176-83.
Score: 0.299
-
Ekong EE, Okenu DN, Mania-Pramanik J, He Q, Igietseme JU, Ananaba GA, Lyn D, Black C, Eko FO. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol. 2009 Mar; 55(2):280-91.
Score: 0.270
-
Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect. 2007 Jun; 40(3):188-200.
Score: 0.244
-
Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol. 2007 Feb; 49(1):46-55.
Score: 0.235
-
Richardson S, Bell CR, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme JU, Eko FO. A novel cold-chain free VCG-based subunit vaccine protects against Chlamydia abortus-induced neonatal mortality in a pregnant mouse model. Front Immunol. 2023; 14:1243743.
Score: 0.190
-
Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, Lyn D, Black CM, Igietseme JU. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine. 2003 Apr 02; 21(15):1694-703.
Score: 0.183
-
Zuo Z, Zou Y, Li Q, Guo Y, Zhang T, Wu J, He C, Eko FO. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge. Sci Rep. 2021 05 17; 11(1):10389.
Score: 0.161
-
Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines. 2011 Nov; 10(11):1585-96.
Score: 0.083
-
He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology. 2007 Sep; 122(1):28-37.
Score: 0.061
-
Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv. 2005 May; 2(3):549-62.
Score: 0.053
-
Igietseme JU, Eko FO, He Q, Bandea C, Black CM. Developing effective delivery systems for Chlamydia vaccines. Curr Opin Mol Ther. 2004 Apr; 6(2):182-94.
Score: 0.049
-
Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004 Feb; 3(1):23-34.
Score: 0.048
-
Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines. 2003 Feb; 2(1):129-46.
Score: 0.045
-
Igietseme JU, Eko FO, He Q, Black CM. Combination vaccines: design strategies and future trends. Expert Rev Vaccines. 2006 Dec; 5(6):739-45.
Score: 0.015